BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 29588546)

  • 21. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.
    Eckerle S; Brune V; Döring C; Tiacci E; Bohle V; Sundström C; Kodet R; Paulli M; Falini B; Klapper W; Chaubert AB; Willenbrock K; Metzler D; Bräuninger A; Küppers R; Hansmann ML
    Leukemia; 2009 Nov; 23(11):2129-38. PubMed ID: 19657361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.
    K Singh V; Werner S; Hackstein H; Lennerz V; Reiter A; Wölfel T; Damm-Welk C; Woessmann W
    Clin Exp Immunol; 2016 Oct; 186(1):96-105. PubMed ID: 27414060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma.
    Singh RR; Cho-Vega JH; Davuluri Y; Ma S; Kasbidi F; Milito C; Lennon PA; Drakos E; Medeiros LJ; Luthra R; Vega F
    Cancer Res; 2009 Mar; 69(6):2550-8. PubMed ID: 19244133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
    Foyil KV; Bartlett NL
    Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination.
    ten Berge RL; Oudejans JJ; Ossenkoppele GJ; Pulford K; Willemze R; Falini B; Chott A; Meijer CJ
    J Clin Pathol; 2000 Jun; 53(6):445-50. PubMed ID: 10911802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The AP-1 transcription factor Batf controls T(H)17 differentiation.
    Schraml BU; Hildner K; Ise W; Lee WL; Smith WA; Solomon B; Sahota G; Sim J; Mukasa R; Cemerski S; Hatton RD; Stormo GD; Weaver CT; Russell JH; Murphy TL; Murphy KM
    Nature; 2009 Jul; 460(7253):405-9. PubMed ID: 19578362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinicopathologic features of 66 cases of anaplastic lymphoma kinase positive and negative systemic anaplastic large cell lymphoma: a comparative study].
    Shi Y; Chen G; Zhou XG; Gong LP; Yu R; Zheng YY; Xie JL; Jin Y
    Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):235-9. PubMed ID: 20654121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.
    Ambrogio C; Voena C; Manazza AD; Martinengo C; Costa C; Kirchhausen T; Hirsch E; Inghirami G; Chiarle R
    Cancer Res; 2008 Nov; 68(21):8899-907. PubMed ID: 18974134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Batf-dependent Th17 cells critically regulate IL-23 driven colitis-associated colon cancer.
    Punkenburg E; Vogler T; Büttner M; Amann K; Waldner M; Atreya R; Abendroth B; Mudter J; Merkel S; Gallmeier E; Rose-John S; Neurath MF; Hildner K
    Gut; 2016 Jul; 65(7):1139-50. PubMed ID: 25838550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anaplastic large cell lymphoma, ALK-negative.
    Ferreri AJ; Govi S; Pileri SA; Savage KJ
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases.
    Agrawal K; Shet T; Sridhar E; Dhende S; Sengar M; Arora B; Laskar S; Gujral S; Menon H; Banavali S
    Indian J Pathol Microbiol; 2017; 60(4):533-540. PubMed ID: 29323068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
    Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
    Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma.
    Cho-Vega JH; Rassidakis GZ; Amin HM; Tsioli P; Spurgers K; Remache YK; Vega F; Goy AH; Gilles F; Medeiros LJ
    Leukemia; 2004 Nov; 18(11):1872-8. PubMed ID: 15385932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Co-expression of CD99/MIC2 and ALK in anaplastic large-cell lymphoma tissues and its significance].
    Zhong L; Wei QZ; Huang XP; Ji TH; Li F; Wang ZQ; Li XZ; Liu JH; Zhao T
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):173-6. PubMed ID: 22781601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.
    Hoareau-Aveilla C; Valentin T; Daugrois C; Quelen C; Mitou G; Quentin S; Jia J; Spicuglia S; Ferrier P; Ceccon M; Giuriato S; Gambacorti-Passerini C; Brousset P; Lamant L; Meggetto F
    J Clin Invest; 2015 Sep; 125(9):3505-18. PubMed ID: 26258416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
    Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
    Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.
    Boi M; Zucca E; Inghirami G; Bertoni F
    Br J Haematol; 2015 Mar; 168(6):771-83. PubMed ID: 25559471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
    Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sensitivity of NK1.1-negative NKT cells to transgenic BATF defines a role for activator protein-1 in the expansion and maturation of immature NKT cells in the thymus.
    Zullo AJ; Benlagha K; Bendelac A; Taparowsky EJ
    J Immunol; 2007 Jan; 178(1):58-66. PubMed ID: 17182540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma.
    Prutsch N; He S; Berezovskaya A; Durbin AD; Dharia NV; Maher KA; Matthews JD; Hare L; Turner SD; Stegmaier K; Kenner L; Merkel O; Look AT; Abraham BJ; Zimmerman MW
    Cell Rep Med; 2024 Mar; 5(3):101472. PubMed ID: 38508140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.